Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
RESEARCH TOOLSreports
Unicycive Therapeutics (UNCY) Stock Price & Analysis
182 Followers
UNCY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.34 - $1.82
Previous Close$0.54
Volume802.53K
Average Volume (3M)648.62K
Market Cap
$20.31M
Enterprise Value$21.23M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$923.00K
Price to Earnings (P/E)―
Beta-4.16
Next Earnings
Aug 12, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.26
Shares Outstanding37,606,630
10 Day Avg. Volume347,859
30 Day Avg. Volume648,616
Standard Deviation0.58
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit31.45
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$5.88Price Target Upside1125.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsUnicycive announced positive results from the safety and tolerability pivotal trial for phosphate binder, oxylanthanum carbonate (OLC).
Market PotentialOLC's low discontinuation rate compares favorably to the 14% discontinuation rate for Fosrenol.
Product AdvantageOLC is formulated as a small pill that is swallowed whole instead of being chewed, making it more convenient for patients.
Bears Say
EarningsUnicycive reported a net loss to common shareholders of $31.4M.
Financial PerformanceOperating expenses have been lowered due to the delay in commercialization, resulting from the additional tolerability study required for NDA filing.
Regulatory DelaysThe need for a tolerability study has delayed commercialization and necessitated the lowering of operating expense forecasts.
---
Ownership Overview
16.60%
Insiders
1.42% Mutual Funds
57.13% Other Institutional Investors
24.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
UNCY FAQ
What was Unicycive Therapeutics’s price range in the past 12 months?
Unicycive Therapeutics lowest stock price was $0.34 and its highest was $1.82 in the past 12 months.
What is Unicycive Therapeutics’s market cap?
Currently, no data Available
When is Unicycive Therapeutics’s upcoming earnings report date?
Unicycive Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 40 days.
How were Unicycive Therapeutics’s earnings last quarter?
Unicycive Therapeutics released its earnings results on May 13, 2024. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.148 by -$0.462.
Is Unicycive Therapeutics overvalued?
According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued.
Does Unicycive Therapeutics pay dividends?
Unicycive Therapeutics does not currently pay dividends.
What is Unicycive Therapeutics’s EPS estimate?
Unicycive Therapeutics’s EPS estimate is -$0.19.
How many shares outstanding does Unicycive Therapeutics have?
Unicycive Therapeutics has 37,606,630 shares outstanding.
What happened to Unicycive Therapeutics’s price movement after its last earnings report?
Unicycive Therapeutics reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.148. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Unicycive Therapeutics?
Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 5M.
---
Unicycive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.88 (1125.00% Upside)
$5.88 (1125.00% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
92.58%
Trailing 12-Months
Company Description
Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
---
UNCY Stock 12 Month Forecast
Average Price Target
$5.88
▲(1125.00% Upside)
Technical Analysis
Best Analysts Covering UNCY
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-16.38%
reiterated a buy rating 8 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -16.38% per trade.
---